1.Enciclopedia Médica en Español. Acccidente cerebrovascular. Disponible en: http://www.nlm.nih.gov/medlineplus/spanish/ency/article/000726.htm 2.Accidente Cerebrovascular: Esperanza en la Investigación. Disponible en: (http://www.ninds.nih.gov/health_and_medical/pubs/accidente_cerebrovascular.htm) 3.WHO. The top ten causes of death. Disponible en: www.who.int/mediacentre/factsheets/fs310/en/index.html 4.Fletcher L, Sanjivan K, Shane M, Sprague B, Scranton R, et al. Intranasal delivery of erythropoietin plus insulin-like growth factor –I for acute neuroprotection in stroke. J Neurosurg 111:164-170, 2009. 5.National Audit Office. Department of Health: progress in improving stroke care. National Audit Office, 2010. 6.AnuarioEstadístico MINSAP, 2010. 7.Navarro T, Henríquez D. Aspectos fisiopatológicos de la neuroprotección: en busca del tiempo perdido. Cuadernos de Neurología 2000; Vol. XXIV. Disponible en: http://escuela.med.puc.cl/paginas/publicaciones/Neurologia/cuadernos/2000/pub_01_2000.html 8.Arauz A, Murillo LM, Bonnin E. Neuroprotección en isquemia cerebral aguda. Estado actual e importancia clínica de la cascada isquémica. Revista Ecuatoriana de Neurología 2002; 11(3). Disponible en: http://www.medicosecuador.com/revecuatneurol/vol11_n3_2002/neuroproteccion.htm 9.Marinello J, Alós J, Carreño P, Olba L, Alexander C. Angiología 1995; 3:151-158. 10.The National Institute of Neurological Disorders and Stroke. rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587. 11.Hacke W, Donnan G, Fieschi C, Kaste M, von KR, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet2004; 363:768-74. 12.Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke; an updated pooled analysis of ECAA, ATLANTIS;NIND, and EPITHET trials. Lancet 2010; 375:1695-703. 13.Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M et al. Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial. Molecular Medicine 2002; 8(8): 495–505. 14.Enfermedad cerebrovascular. Tratamiento de la enfermedad cerebrovascular oclusiva. Disponible en: http://www.iladiba.com.co/upr/1998/NO21998/HTM/ACV3.asp 15.Mc Arthur K, Quinn T, Dawson J, Walters M. Diagnosis and treatment of transient ischemic attack and ischemic stroke in the acute phase. BMJ 2011; 342:d 1938 doi: 10, 1136/bmj.d1938. 16.Ehrenreich H, Aust C, Krampe H, Jahn H, Jacob S, Herrmann M, Sirén AL. Erythropoietin: Novel approaches to neuroprotection in human brain disease. Metabolic Brain Disease Dec 2004; 19(3/4):195-206. 17.Sirén AL, Ehrenreich H. Erythropoietin-a novel concept of neuroprotection. Eur Arch Psychiatry ClinNeurosci 2001; 251:179-184. 18.Brines ML, Ghezzi P, Keenan S, Agnello D, deLanerolle NC, Cerami C et al. From the cover: erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. ProcNatlAcadSci USA 2000; 19: 10526-31. 19.Giuseppe R, Luigi M. Hematologic Consequences of Renal Failure. Brenner and Rector’s. The Kidney, Sixth Edition 2000; 2079-2102. 20.Miyake T, Kung CK-H, Goldwasser E. Purification of human erythropoietin. J BiolChem 1977; 252: 5558-5564. 21.Koury ST, Bondurat MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridisation. Blood 1988; 71:524-7. 22.Juul SE, Stallings SA, Christensen RD. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res 1999; 46: 543 547. 23.Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998; 43: 40 49. 24.Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996; 8: 666 676. 25.Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J BiolChem 1994; 269: 19488 19493. 26.Eschbach JW, Nelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321: 158-163. 27.Goodnough LT, Monk TG, Andriole GL. Current concepts: erythropoietin theraphy. N Engl J Med 1997; 336: 933-938. 28.Allegro A, Galasso A, Siracusano L, Aloisi C, Corica F, Lagana A et al. Administration of recombinant erythropoietin determines increase of peripheral resistances in patients with hypovolemic shock. Nephron 1996; 74: 431-432. 29.Buemi M, Denuzzo G, Allegra A, Aloisi C, Squadrito F, Squadrito G et al. Recombinant human erythropoietin inhibits the cutaneous vasodilatation induced by acetyl-choline. Int J Microcirc 1995; 15: 283-286. 30.Buemi M, Allegra A, Aloisi C, Frisina N. Influence of therapy with recombinant erythropoietin on serum levels of neopterin in hemodialyzed subjects. Am J Nephrol 1991; 11: 281-283. 31.Kokot F, Wiecek A, Grzesczak W, Klepacka J, Klin M, Lao M. Influence of erythropoietin treatment on endocrine abnormalities in hemodialyzed patients. ContribNephrol 1989; 76: 257-270. 32.Calapai G, Marciano MC, Corica F, Allegra A, Parisi A, Frisina N et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 2000; 401: 349-356. 33.Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M et al. Erythropoietin and the brain: from neurodevelopment to neuroprotection. Clinical Science 2002; 103:275-282. 34.Grasso G, Sfacteria A, Cerami A, Brines M. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? The Neuroscientist 2004; 10(2):93-98. 35.Bartesaghi S, Marinovich M, Corsini E, Galli CL, Viviani B. Erythropoietin: a novel neuroprotective cytokine. Neurotoxicology 2005; 26: 923-928. 36.Masuda S, Nagao M, Takahata K, et al. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J BiolChem 1993; 268:11208–11216. 37.Marti HH, Gassmann M, Wenger RH, Kvietikova I, Morganti-Kossmann MC, Kossmann T, et al. Detection of erythropoietin in human cerebrospinal fluid: intrinsic erythropoietin production in the brain. Kidney Int 1997; 51: 416-418. 38.Digicaylioglu M, Bichet S, Marti HH, et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. ProcNatlAcadSci USA 1995; 92: 3717–3720. 39.Morishida E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997; 76: 105-116. 40.Bernaudin M, Bellail A, Marti HH, et al. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 2000; 30: 271–278. 41.Shingo T, Sorokan ST, Shimazaki T, Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001; 21: 9733-9743. 42.Yamaji R, Okada T, Moriya M, Naito M, Tauruo T, Miyatake K, Nakano Y. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 1996; 239: 494-500. 43.Sirén AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. ProcNatlAcadSci USA 2001; 98(7): 4044-4049. 44.Chattopadhyay A, Choudhury TD, Bandyopadhyay D, Datta AG. Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. BiochemPharmacol 2000; 59:419–425. 45.Genc S, Akhisaroglu M, Kuralay F, Genc K. Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro. NeurosciLett 2002; 321:73–76. 46.Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, Ghezzi P. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 2002; 952:128–134. 47.Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198(6):971–975. 48.Campana WM, Myers RR. Erythropoietin and erythropoietin receptors in the peripheral nervous system: Changes after nerve injury. Faseb J 2001; 15:1804–1806. 49.Sasaki R, Masuda S, Nagao M. Pleiotropic functions and tissue-specific expression of erythropoietin. News PhysiolSci 2001; 16:110–113. 50.Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J BiolChem 2001; 276:39469–39475. 51.Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. RestorNeurolNeurosci 2004; 22(2):105-119. 52.Sirén AL, Knerlich F, Poser W, Gleiter C, Brück W, Ehrenreich, H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. ActaNeuropathol 2001; 101:271–276. 53.Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res Aug 2004;63(2):208-216. 54.Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. ProcNatlAcadSci, 2003 May 27; 100(11):6741-6746. 55.Kaptanoglu E, Solaroglu I, Okutan O, Surucu HS, Akbiyik F, Beskonakli E. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings. Neurosurg Rev Apr 2004;27(2):113-120. 56.Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. ActaPaediatrSuppl 2002;91(438):36-42. 57.Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. ProcNatlAcadSci U S A. 1998 Apr 14;95(8):4635-40. 58.Cerami A, Brines M, Ghezzi P, Cerami C, Itri LM. Neuroprotective properties of epoetinalfa. Nephrol Dial Transplant 2002; 17 [Suppl 1]: 8–12. 59.Celik M, Gokmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. ProcNatlAcadSci U S A. 2002 Feb 19;99(4):2258-63. 60.Yu YP, Xu QQ, Zhang Q, Zhang WP, Zhang LH, Wei EQ. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. NeurosciLett 2005 Oct 14;387(1):5-10. 61.Minnerup J, Heidrich J, Rogalewski A, Schabit WR, Wellann J. The Efficacy of Erytrhopoietin and its analogues in Animal Stroke Models. A meta-analysis. Stroke, 2009; 40:3113-3120. 62.Digicaylioglu M, Bichet S, Marti HH, Wenger RH, Ivas LA, Bauer C, Gassmann M. Localization of specific erythropoietin binding sites in defined areas of mouse brain. ProcNatlAcadSci USA 1996; 92: 3717-3720. 63.Li Y, Juul SE, Morris-Wiman JA, Calhoun DA, Cristensen RD. Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses. Pediatr Res 1996; 40: 376-380. 64.Bohlius J, Langensiepen S, Schwarzer G, Engert A. Epoetin in the treatment ofmalignant disease: A comprehensive meta-analysis. Blood 2002; 100:3430A. 65.Jelkmann W. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharm Biotechnol 2000; 1:11–31. 66.Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K et al. Recombinant human erythro¬poietin in the treatment of acute ischemic stroke. Stroke 2009; 40:e647-656. 67.Gene, S., Koroglu, T.F., and Gene, K. (2004) Erythropoietin and the nervous system. Brain Res. 1000, 19 31. 68.GarcíaRodriguez,J.C., and Sosa, T.I., (2009) The nasal route as a potencial pathway for delivery of Erythropoietin in the treatment of acute ischemic stroke in humans. TheScientificWorldJournal 9. 970-981. 69.Bahadur, S.; Pathak K. Physicochemical and physiological considerations for efficient nose-to-brain targeting. Expert Opin. Drug Deliv., 2012, 9(1),19-31. 70.Hanson, L.R.; Frey, W.H. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neuroscience, 2008, 9(Suppl 3), S5. 71.Sosa, I., García Rodríguez J.C., Santana, J., et al (2006) Intranasal administration of recombinant human erythropoietin exerts neuroprotective effects on post-ischemic brain injury in Mongolian gerbils. Pharmacology Online 1, 100-112. 72.Sosa, I., Cuz, J., et al (2007) Paso de la molécula de eritrppoyetina humana recombinante con bajo contenido de acido sialico al Sistema nervioso central por la vía intranasal en los modelos del meriones unguicularus y el primate no humano Macaca fascicularis. Rev. Salud. Anim. 29(2), 1}6. 73.Nuñez, Y., Bueno, P.V., Carrillo, D.C., et al. (2009) Neuroprotective effect of a nasal formulation of erythropoietin with low salicaci content. Rev. Cubana Farm. 43(1), 1´13 74.Rodríguez, Y.; Mengana, Y.; Muñoz, A.; Subirós, N.; González-Quevedo, A.; Sosa, I.; García, J.C. Treatment with Nasal Neuro-EPO Improves the Neurological, Cognitive, and Histological State in a Gerbil Model of Focal Ischemia. The Scientific World JOURNAL, 2010, 10, 2288–2300. 75.Gao, Y, et al. Different expression patterns of Ngb and EPOR in the cerebral cortex and Hyppocampus revealed distintic therapeutic effects of intranasal delivery of NeuroEPO for ischemic insults to the Gerbil brain. J Histochem and cytochem, 2011, 59, 214-228. 76.Lagarto, A.; Bueno, V.; Guerra, I.; Valdés, O.; Couret, M.; López, R.; Vega, Y. Absence of hematological side effects in acute and subacute nasal dosing of erythropoietin with a low content of sialic acid. Exp. Toxicol. Pathol. 2011, 63(6), 563-567. 77.US Department of health and Human Services. Food and Drug Administration. Pharmacology and Toxicology. July 2005. Center for Drug Evaluation and Research. Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy individuals. Disponible en: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm065014.htm. 78.CENPALAB. Estudio del efecto de la aplicación intranasal de NeuroEPO sobre algunos parámetros hematológicos y evaluación de efectos adversos en los modelos de la rata Sprague Dawley, la especie de primate no humano Macaca Fascicularis, y el modelo de isquemia unilateral permanente en el Gerbo de Mongolia. Informe Final. Febrero. 2012. 79.Shyeilla V, Hanson L, Frey W. Intranasal delivery to the Central Nervous System: Mechanism and Experimental Considerations. J Pharm Scie 99:1654-1673, 2010. 80.Lagarto A, et al. Informe del potencial hematopoyético de una formulación nasal de eritropoyetina humana recombinante con bajo contenido de ácido siálico. Informe Final TOX/27/09. CIDEM. 2012. 81.CIMAB. Reporte periódico integrado de seguridad. Epoietina alfa.2011. 82.Common Terminology Criteria for adverse events v3.0 (CTCAE). 2006. En: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf 83.CECMED. Regulación 21-08. Requisitos para la autorización y modificación de ensayos clínicos. 2008. 84.W.H.O. The causality assessment of suspected adverse reactions. En: www.who-umc.org. 2006. 85. Buoen, C, et al. How first time in human studies are being performed. A survey of phase I dose escalation trials in healthy volunteers published between 1995 and 2004. J Clin Pharmacol 45: 1123, 2005.
